How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,911 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Vaccination of HIV infected children

– 13-valent pneumococcal conjugate vaccine Hib/MenC - Haemophilus influenzae type b and Neisseria meningitidis capsular group C conjugate vaccine MenC - meningococcal capsular group C conjugate vaccine 4CMenB – multicomponent meningococcal capsular group B protein vaccine LAIV – live attenuate influenza vaccine MMR – measles, mumps, rubella vaccine HPV – human papilloma virus vaccine MenACWY – quadrivalent meningococcal capsular groups A, C, W and Y conjugate vaccine Hep A&B – combined hepatitis (...) years old (females & males) Cervical cancer caused by human papillomavirus (HPV) types 16 &18; genital warts caused by types 6 & 11 HPV x 3 doses (0, 1, 6 months) Gardasil Upper arm 14 years old (school year 9) Tetanus, diphtheria and polio Meningococcal groups A, C, W, Y disease Hepatitis A and B dTaP/IPV (check MMR status) MenACWY Hep A and B, booster dose or primary course (if previously unimmunised) Revaxis Nimenrix or Menveo Twinrix or Ambirix Upper arm Upper arm Upper arm Notes: 1. All infants

2018 The Children's HIV Association

162. Canadian HIV Pregnancy Planning Guidelines

Standards Association guidelines for infection control when handling HIV-positive materials and use additional procedures available for the processing of HIV-positive sperm to ensure the preparation of a virus-free sample (III-A). 35. Potentially infectious samples should be processed in a separate laboratory or dedicated area with separate equipment within the main laboratory to reduce the risk of HIV contamination (III-A). 36. Potentially infectious gametes and embryos should be stored (...) Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal

2018 Society of Obstetricians and Gynaecologists of Canada

163. HIV

contact us via jon.brassey@tripdatabase.com Top results for hiv 1. HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS - Summary The Human Immunodeficiency Virus ( HIV ) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV : HIV -1 (the predominant type in the UK) is highly virulent and is found (...) Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV . Key considerations concerning the issue 2011 9. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes

2018 Trip Latest and Greatest

164. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class (...) Practice GEN elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated; Genvoya®) GI gastrointestinal GLSM geometric least-squares mean GS-9883 bictegravir HBeAb hepatitis B e antibody HBeAg hepatitis B e antigen HBsAb hepatitis B surface antibody HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HDPE High Density Polyethylene HIV human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HLA human leukocyte antigen HPLC High performance liquid

2018 European Medicines Agency - EPARs

165. Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV

Environmental Risk Assessment GC-HS Gas Chromatography head space HDPE High Density Polyethylene HIV Human Immunodeficiency Virus HBV Hepatitis B Virus HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements IR Infrared KF Karl Fischer titration LDPE Low Density Polyethylene Ph. Eur. European Pharmacopoeia RMP Risk Management Plan T max Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax was defined (...) Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of 5 times the ULN, intenuption or discontinuation of treatment must be considered. • Advice to monitor the liver enzymes of patients treated with other medicinal products associated with liver toxicity. • Warning that reports of hepatic failure have

2018 European Medicines Agency - EPARs

166. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

. • A negative serological test in children who have had a positive HIV RNA PCR test does not exclude ongoing HIV infection. • A detailed history of any possible previous ART given to the child and/or mother (or other likely source of infec- tion) should be documented. • The genotypic HIV resistance pro?le should be docu- mented at baseline. • The human leucocyte antigen (HLA) B*5701 genotype shouldbecon?rmednegativebeforeusingabacavir(ABC). • Clinical assessment should be carried out 3-4-monthly in children (...) infants at low risk of HIV transmission (maternal VL 100000 copies/ml); • in asymptomatic children aged 1–3 years irrespective of immune status and VL; • in sexually active adolescents, to minimize the risk of onward transmission; • in the presence of any signi?cant HIV-related clinical symptoms; • in hepatitis B virus (HBV) coinfection irrespective of immune status. 6. Which ART regimen to start as ?rst-line therapy • Children should start effective (at least three drugs) ART, usually a dual

2018 The Children's HIV Association

167. Preparing HIV-infected children and adolescents for travel

, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49(3):272-5. 7. Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clin Vaccine Immunol. 2012;19(11):1751-7. 8. Crane HM, Dhanireddy S, Kim HN, et al. Hepatitis A vaccination among human immuno- deficiency (...) . Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2000;30(1):218. 15. WHO. Vaccines and vaccination against yellow fever: WHO Position Paper. June 2013. http://www.who.int/wer/2013/wer8827.pdf?ua=1. 16. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48(5):659-66. 20 17. Staples JE, Bocchini JA, Jr., Rubin L

2018 The Children's HIV Association

168. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019) Guideline Development Group: Cara Saxon (Lead Author), Anne Edwards, Riina Rautemaa- Richardson, Caroline Owen, Bavithra Nathan, Bret Palmer, Clare Wood, Humera Ahmed, Sameena Ahmad, Patient Representatives, Mark FitzGerald (CEG Editor) Clinical Effectiveness Group (...) (CEG), British Association for Sexual Health and HIV (BASHH) NEW IN THE 2019 GUIDELINES Terminology: • The new guidelines refer to ‘acute’ and ‘recurrent’ vulvovaginal candidiasis (VVC) and no longer use the terms ‘uncomplicated’ and ‘complicated’ VVC; the new definitions are felt to be more reflective of how women with VVC typically present to clinical services and are subsequently managed • The elements of complicated VVC where single dose treatments are not always appropriate are still covered

2019 British Association for Sexual Health and HIV

169. Maintaining and improving quality of care within HIV clinical services

and human rights gaps remain: key populations are underserved, experience persistent stigma and discrimination and are subject to criminalization, violence and other human rights abuses (2). To address these gaps and reach global targets, HIV programmes must establish and maintain systems for ensuring a high level of quality in service delivery, within the framework of universal health coverage and supported by national quality policies and strategies. Three seminal 2018 publications (1,3,4) have (...) , district and facility levels and are people-centred. Delivery of quality services depends on all the building blocks of health systems, including optimized management, funding, human resources for health, information systems and procurement of high-quality drugs, laboratory supplies and commodities. In accordance with the 2016 WHO consolidated HIV treatment guidelines (7), quality HIV services should: • provide people-centred care; • offer safe, acceptable and appropriate clinical and non- clinical

2019 World Health Organisation HIV Guidelines

170. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

antiretroviral medications are taken by HIV-negative people prior to exposure to the virus to prevent infection. Once-daily oral tenofovir/emtricitabine, as a fixed dose combination tablet, has been licensed and available for use as PrEP in Ireland since 2016. Policy provision for PrEP is contained in the National Sexual Health Strategy 2015–2020, with Priority Action 3 calling for ‘the appropriate use of antiretroviral therapy in HIV prevention’. A PrEP programme provides PrEP medication along with holistic (...) to uncertainty in the parameters. PrEP effectiveness was the main driver of cost-effectiveness in the model. ? The mean number of people expected to join the programme in year one is 1,705 people (95% CI: 617 to 3,452) based on model calibration to the observed number who enrolled in Scotland’s national programme. On average, 173 HIV infections are estimated to be averted over the course of the first five years in the base case analysis. ? In the first year, PrEP medications alone are estimated to cost €1.1m

2019 Health Information and Quality Authority

171. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV

), Kogie Naidoo (CAPRISA, South Africa), Eyerusalem Negussie (Ministry of Health, Ethiopia), Cédric Nininahazwe (Global Network of Young People Living with HIV, Netherlands), Sylvia Ojoo (Institute of Human Virology of the University of Maryland, Kenya), Andrew Prendergast (Queen Mary, University of London, United Kingdom and Zvitambo Institute, Zimbabwe), Elliot Riazes (United States Centers for Disease Control and Prevention, USA), Nathan Shaffer (independent consultant), George Siberry (Office (...) informed the development of these guidelines and should guide the implementation of the recommendations. • The guidelines should contribute to realizing the Sustainable Development Goals by achieving key global and national HIV goals. • These guidelines are based on a public health approach to scaling up the use of ARV drugs along the continuum of HIV prevention, care and treatment. • Implementation of these guidelines needs to be accompanied by efforts to promote and protect the human rights of people

2019 World Health Organisation HIV Guidelines

172. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Pathophysiology in HIV: Metabolic Contributors HIV infection is associated with metabolic complications, including dyslipidemia, insulin resistance, and body composition changes, which can contribute to CVD. Initially, dyslipidemia in HIV was characterized by increased triglyceride levels, thought to be related to immunodeficiency in the pre-ART era. Later, specific ART medications, including several protease inhibitors (PIs) and efavirenz, a non–nucleoside reverse transcriptase inhibitor (NRTI), were (...) Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May

2019 American Heart Association

173. Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. (Abstract)

Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. Despite the increasing evidence for chemoradiotherapy as standard treatment for anal cancer in patients with HIV infection, there is still some uncertainty regarding increased toxicity and adverse effects on the immune status.We report the clinical outcome of 5-fluorouracil/mitomycin C-based concurrent chemoradiotherapy (...) for anal carcinoma in patients with HIV infection with an emphasis on the long-term course of CD4 counts and the HIV-related morbidity during follow-up.A retrospective single-institution chart review was performed.Between 1997 and 2012, 36 HIV-positive patients were treated with standard chemoradiotherapy (median tumor dose, 54 (range, 50.4-60.4) Gy at 1.8 Gy/fraction; 5-fluorouracil, 800-1000 mg/m(2), days 1-4 or 1-5; mitomycin C, 10 mg/m(2), day 1, in the first and fifth week).A retrospective

2014 Diseases of the Colon & Rectum

174. Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? (Abstract)

Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? High rates of partner change in 'upstream' sex work networks have long been recognized to drive 'downstream' transmission of sexually transmitted infections (STIs). We used a stochastic microsimulation model (STDSIM) to explore such transmission dynamics in a generalized African HIV epidemic.We refined the quantification of sex work in Kisumu, Kenya (...) , from the 4-cities study. Interventions with sex workers were introduced in 2000 and epidemics projected to 2020. We estimated the contribution of sex work to transmission, and modelled standard condom and STI interventions for three groups of sex workers at feasible rates of use and coverage.Removing transmission from sex work altogether would have resulted in 66% lower HIV incidence (range 54-75%) and 56% lower prevalence (range 44-63%) after 20 years. More feasible interventions reduced HIV

2014 AIDS

175. The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock

The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03335124

2017 Clinical Trials

176. Higher Transplacental Pathogen-Specific Antibody Transfer Among Pregnant Women Randomized to Triple Antiretroviral Treatment Versus Short Course Zidovudine. Full Text available with Trip Pro

Higher Transplacental Pathogen-Specific Antibody Transfer Among Pregnant Women Randomized to Triple Antiretroviral Treatment Versus Short Course Zidovudine. HIV-1 infection may impair transplacental antibody transfer to infants. The impact of highly active antiretroviral treatment (ART) given during pregnancy on transplacental antibody transport is unknown.HIV-1 infected pregnant women with CD4 counts between 200 - 500 were randomized to short-course zidovudine (ZDV) or triple ART at 32 weeks (...) gestation for prevention of mother-to-child HIV-1 transmission. Levels of maternal antibody against measles, pneumococcus and rotavirus at delivery, and antibody transfer to the baby through cord blood, were compared between trial arms.Overall, 141 and 148 women were randomized to triple ART and ZDV, respectively; cord blood was available for a subset (n = 20 in triple ART and n = 22 in ZDV). Maternal antibody levels to all pathogens during pregnancy and at delivery were not significantly different

2017 Pediatric Infectious Dsease Journal

177. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. (Abstract)

(in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 IU/mL pre-LT.A total of 42 hepatitis B surface antigen (HBsAg) positive, human immunodeficiency virus and hepatitis D virus-negative patients with pretransplant HBV DNA undetectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and daily for 5 days together with nucleos(t)ide analogues indefinitely yielded 1- and 3-year cumulative incidences of recurrence, defined by positive serum HBsAg, of 2.9% (upper 95 (...) Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Hepatitis B immune globulin (HBIG) has been an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantation (LT) recipients, but HBIG is costly and inconvenient to administer, prompting consideration of alternative regimens.In this retrospective cohort, we report on the success of antiviral therapy combined with a short course

2017 Transplantation

178. Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma). Unable tolerate an MRI, or have a contraindication to MRI. Active infection requiring systemic therapy. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV antibody) indicating acute or chronic infection. Vaccination within 4 weeks of the first dose of study (...) Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

179. A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? Full Text available with Trip Pro

A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? 28809515 2017 12 13 2018 12 02 1535-4970 196 4 2017 08 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? 411-413 10.1164/rccm.201704-0759ED Randolph Adrienne G AG 0000-0002-3084-3071 1 Department of Anesthesiology, Perioperative and Pain Medicine (...) ppublish 28809515 10.1164/rccm.201704-0759ED PMC5564677 PLoS One. 2014 Mar 13;9(3):e92121 24626215 Clin Pharmacol Ther. 2001 Mar;69(3):89-95 11240971 PLoS One. 2014 Jan 29;9(1):e86242 24489704 Crit Care Med. 2016 Nov;44(11):2010-2017 27513537 Crit Care Med. 1996 May;24(5):743-52 8706448 Expert Opin Med Diagn. 2013 Jan;7(1):37-51 23335946 Crit Care Med. 2013 Jul;41(7):1761-73 23685639 Pediatr Crit Care Med. 2005 Jan;6(1):2-8 15636651 Crit Care. 2012 Oct 01;16(5):R174 23025259 Curr Opin HIV AIDS. 2010

2017 American Journal of Respiratory and Critical Care Medicine

180. Time-course, negative-stain electron microscopy–based analysis for investigating protein–protein interactions at the single-molecule level Full Text available with Trip Pro

and potentially capture states that are unobservable with ensemble methods because they are below the limit of detection or not conducted on an appropriate time scale. Using the HIV-1 envelope glycoprotein (Env) and its interaction with receptor CD4-binding site neutralizing antibodies as a model system, we both corroborate ensemble kinetics-derived parameters and demonstrate how time-course EM can further dissect stoichiometric states of complexes that are not readily observable with other methods (...) Time-course, negative-stain electron microscopy–based analysis for investigating protein–protein interactions at the single-molecule level Several biophysical approaches are available to study protein-protein interactions. Most approaches are conducted in bulk solution, and are therefore limited to an average measurement of the ensemble of molecular interactions. Here, we show how single-particle EM can enrich our understanding of protein-protein interactions at the single-molecule level

2017 The Journal of biological chemistry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>